These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29061943)

  • 21. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets.
    Knauf JA; Fagin JA
    Curr Opin Cell Biol; 2009 Apr; 21(2):296-303. PubMed ID: 19231149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.
    Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
    Eur J Cancer; 2017 Mar; 73():85-92. PubMed ID: 28169047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
    Halilovic E; Solit DB
    Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.
    Shelly S; Chien MB; Yip B; Kent MS; Theon AP; McCallan JL; London CA
    Mamm Genome; 2005 Mar; 16(3):211-7. PubMed ID: 15834638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
    Pohl G; Ho CL; Kurman RJ; Bristow R; Wang TL; Shih IeM
    Cancer Res; 2005 Mar; 65(5):1994-2000. PubMed ID: 15753399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma].
    Zaleśna I; Hartman ML; Czyż M
    Postepy Hig Med Dosw (Online); 2016 May; 70():471-88. PubMed ID: 27180965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic strategies for targeting BRAF in human cancer.
    Pratilas CA; Solit DB
    Rev Recent Clin Trials; 2007 May; 2(2):121-34. PubMed ID: 18473997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.
    Tutuka CSA; Andrews MC; Mariadason JM; Ioannidis P; Hudson C; Cebon J; Behren A
    Mol Cancer; 2017 Jun; 16(1):112. PubMed ID: 28659148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical
    Dumaz N; Jouenne F; Delyon J; Mourah S; Bensussan A; Lebbé C
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31398831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
    Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
    Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
    Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.
    Ellerhorst JA; Ekmekcioglu S; Johnson MK; Cooke CP; Johnson MM; Grimm EA
    Oncogene; 2006 Jun; 25(28):3956-62. PubMed ID: 16474847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
    Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
    Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
    Zafon C; Obiols G
    Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF inhibitors in clinical oncology.
    Morris V; Kopetz S
    F1000Prime Rep; 2013; 5():11. PubMed ID: 23585929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape.
    Vanni I; Tanda ET; Spagnolo F; Andreotti V; Bruno W; Ghiorzo P
    Front Mol Biosci; 2020; 7():113. PubMed ID: 32695793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.